Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Mylan enters generic insulin agreement with Biocon

Feb. 18, 2013

St George's and Orphan Technologies sign agreement to develop new therapies for metabolic disorders

Feb. 15, 2013

Vanderbilt University and GSK to develop novel treatments for severe obesity

Feb. 15, 2013

Oramed Pharmaceuticals gives update on IND for oral insulin

Feb. 15, 2013

Ventria Bioscience and USC receive grant for fusion protein

Feb. 15, 2013

Novo Nordisk gains price approval in Japan for once-daily basal insulin

Feb. 14, 2013

Prolor Biotech's hGH-CTP receives orphan drug designation in Europe

Feb. 14, 2013

Pfizer designs new glucagon receptor antagonists

Feb. 14, 2013

Amylin Pharmaceuticals patents new fusion proteins

Feb. 14, 2013

Further preclinical work supports potential use of ISCO's hpSC-derived hepatocytes

Feb. 13, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...